Rainbow BioSciences, the biotechnology subsidiary of Rainbow Coral Corp. , continues its negotiations toward a definitive pharma partnering agreement with emerging biotech innovator Amarantus BioSciences .
RBCC is in talks to provide funding and expertise towards the development and marketing of one or more of Amarantus’ exciting medical breakthroughs. The company is developing thrilling new ways to effectively diagnose and treat devastating neurological disorders including Parkinson’s disease and Traumatic Brain Injury (TBI).
Amarantus owns the rights to a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis as well as the license to a groundbreaking diagnostic platform called NuroPro that allows neurologists to accurately diagnose and track the progression of Parkinson’s disease in patients.
“The breakthroughs that Amarantus is currently working on don’t exist in the marketplace today,” said RBCC CEO Patrick Brown. “Their therapeutic potential is enormously exciting, and we have high hopes for both their disease-fighting abilities as well as their immediate commercial appeal.”
Rainbow BioSciences is working to develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ: CTIC), Biogen Idec Inc. (NASDAQ: BIIB) and Elan Corp. (NYSE: ELN).
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity